NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City
SHELTON, CONNECTICUT -- Tuesday, June, 13, 2017 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, reports that its CEO, Eugene Seymour, MD, MPH., will describe the Company's progress towards human clinical trials stage at the 2017 Marcum Investor Conference. The Conference is being held on Thursday, June15th, 2017, at the Grand Hyatt Hotel in New York City. Dr. Seymour's talk is scheduled for 11:30am.
The Company has recently reported that its drug candidates for topical treatment of shingles were almost five times more effective compared to acyclovir in cell culture studies. Moreover, no cytotoxicity was observed at any of the doses tested for the Company's drug candidates.
The Company has previously reported that treatment with certain herpecide drug candidates led to complete survival of small animals lethally infected with the aggressive and neurotropic HSV-1 strain H129c, wherein all of the untreated animals died. Those animal studies also reproducibly demonstrated dramatic improvements in clinical symptoms associated with herpes simplex virus infection. HSV-1 causes herpes labialis or "cold sores", and is also linked to Alzheimer's disease.
The Company has expanded its HerpeCide™ program into development of topical treatments for (a) herpes labialis (HSV-1), (b) genital herpes (HSV-2), (c) shingles (VZV), and (d) herpes keratitis. Of these, the shingles treatment program is currently the most advanced and is rapidly moving towards clinical candidate selection.
There is no animal model for shingles because the causative virus, VZV (aka human herpesvirus-3 or HHV-3), does not infect animals. A model based ex vivo human skin patch infection by VZV has been developed by Dr. Jennifer Moffat at SUNY Upstate Medical University in Syracuse, NY. As previously reported, the Company's nanoviricides are currently being tested for their antiviral effects in this human skin model. The Company believes that its drug candidates should show effectiveness in this model, given the strong efficacy observed in the cell culture model.
The Company believes that its shingles treatment program is moving more rapidly towards human clinical trials compared to the HSV-1 herpes labialis treatment program. The Company is working on scaling up the production of the drug candidates for both of these programs to the quantities needed for Safety and toxicology studies, as well as for initial human clinical trials, under appropriate guidelines.
(www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to
dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other
written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and
unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially
affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ
materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of
principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and
market acceptance of our products.
FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.
Anil R. Diwan